Holocene Advisors
XENE icon

Holocene Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Holocene Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,518,686
Closed -$88.3M – 1023
2026
Q1 		$88.3M Buy
1,518,686
+236,605
+18% +$10.9M 0.21% 121
2025
Q4 		$57.5M Sell
1,282,081
-694,472
-35% -$29.2M 0.12% 193
2025
Q3 		$79.4M Buy
1,976,553
+167,078
+9% +$5.88M 0.18% 135
2025
Q2 		$56.6M Buy
+1,809,475
New +$59M 0.14% 156
2023
Q4 		– Sell
-178,470
Closed -$6.1M – 856
2023
Q3 		$6.1M Sell
178,470
-534,008
-75% -$20M 0.03% 359
2023
Q2 		$27.4M Sell
712,478
-273,717
-28% -$10.9M 0.12% 186
2023
Q1 		$35.3M Sell
986,195
-205,443
-17% -$7.59M 0.17% 161
2022
Q4 		$47M Sell
1,191,638
-637,514
-35% -$23.2M 0.29% 108
2022
Q3 		$66M Hold
1,829,152
– – 0.42% 82
2022
Q2 		$55.6M Buy
1,829,152
+919,524
+101% +$27.8M 0.34% 103
2022
Q1 		$27.8M Buy
+909,628
New +$27.2M 0.14% 164

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Holocene Advisors's XENE Position: Q2 2026 in Review

Holocene Advisors sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 1,518,686 shares — an estimated $88.3M sold.

Holocene Advisors first reported a position in XENE in Q1 2022 and held it in 11 quarters. The position peaked at $88.3M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Holocene Advisors reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Holocene Advisors sold 1,518,686 Xenon Pharmaceuticals shares in Q2 2026, an estimated $88.3M.
  • Holocene Advisors first reported a position in Xenon Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Holocene Advisors's Xenon Pharmaceuticals position peaked at $88.3M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.